Psilocybin, the compound in so-called magic mushrooms, remains one of the most tightly restricted substances in British law even as UK scientists, universities and biotech companies help drive its emergence as a serious candidate for treating depression, addiction and eating disorders.
Clinical trial data are increasingly positive and government advisers have recommended easing research barriers, yet a person seeking the drug outside a trial has, in practice, only illegal or overseas routes open to them.
Below is where the law stands, what regulators and researchers are doing about it, and how that compares with faster-moving reforms in the United States, the European Union and Australia.
Psilocybin Remains a Class A Drug With No Recognised Medicinal Use
Under the Misuse of Drugs Act 1971, psilocybin and its active metabolite psilocin are Class A controlled substances, the UK’s most serious category, alongside heroin and cocaine. They also sit in Schedule 1 of the Misuse of Drugs Regulations 2001, the tier reserved for drugs deemed to have no recognised medicinal use, meaning possession, production and supply are criminal offences carrying up to seven years for possession and life imprisonment for supply, with no exemption for religious, personal or therapeutic use.
Mind Forward London will gather world-class researchers, clinicians and investors working to bring the future of mental health innovation to reality. Join them on December 1st in London’s Ministry of Sound.
That reach extends beyond dried or prepared mushrooms. Since the Drugs Act 2005 closed what had been a loophole for fresh fungi, any mushroom material containing psilocybin, whether fresh, dried or prepared, is controlled the moment it is picked or cultivated. Spores are the exception: biologically dormant and free of psilocybin until the fungus fruits, they fall outside the law, which is what allows a trade in spore prints and syringes to operate openly online.
British Science Is Producing Some of the Field’s Strongest Data
Academic research has advanced faster than the regulatory framework around it. Imperial College London’s Centre for Psychedelic Research, the first of its kind in the world, has secured funding from the National Institute for Health and Care Research and the Office for Life Sciences.
At King’s College London, the Psychoactive Trials Group led by Professor James Rucker ran the country’s first publicly-funded randomised trial of psilocybin for treatment-resistant depression, reported encouraging results, and is now recruiting for a trial in anorexia nervosa as well as hosting a site for Compass Pathways’ own depression programme.
The University of Exeter, which already runs the world’s first postgraduate course dedicated to psychedelics, has meanwhile just been awarded £2.5 million from the Wellcome Trust, alongside the University of Leicester, for a five-year study of how people already use psilocybin, LSD and MDMA therapeutically outside clinical settings, a direct academic response to the gap between restrictive law and widespread unregulated use.
Commercially, London-headquartered Compass Pathways, which opened a UK psilocybin Phase 3 trial site in 2023, reported in June 2025 that its synthetic therapy COMP360 hit its primary endpoint in a first Phase 3 trial for treatment-resistant depression, then followed up with a second successful Phase 3 trial and six-month durability data, positioning the company, in chief executive Kabir Nath’s words, as potentially the first to bring a classic psychedelic to market, with a rolling submission to the U.S. Food and Drug Administration due to complete by the end of 2026.
UK biotech Beckley Psytech, spun out of Amanda Feilding’s Beckley Foundation, reported positive mid-stage results for its intranasal drug BPL-003 before merging into Atai Life Sciences; that combined company is now the subject of Eli Lilly’s up-to-$3.8 billion acquisition, announced in July 2026 as the largest Big Pharma bet on psychedelics to date.
London has also built out the sector’s supporting infrastructure, from contract researcher Clerkenwell Health, whose recent appointment cemented its role as a key European psychedelics player, to the PSYCH Symposium, which Drug Science founder David Nutt and other organisers have billed as Europe’s leading psychedelic medicine gathering.
Following on the success of the 2025 PSYCH Symposium, Mind Forward is hosting Mind Forward London 2026, where psychedelic research will be covered among other groundbreaking mental health biotech.
Outside a Trial, Access Runs Through the Grey Market or Abroad
For anyone not enrolled in a clinical trial, legal access to psilocybin in the UK does not yet exist— what exists instead is a patchwork of workarounds.
Spore vendors sell openly because spores are lawful, and some buyers use them to cultivate mushrooms illegally at home. Underground and semi-underground guides and therapists operate in a grey area. Some patients instead lean toward retreats in the Netherlands, Portugal, Costa Rica and Mexico, where psilocybin truffles or mushrooms are legal, decriminalised or tolerated, typically costing £2,000 to £5,000 once travel is included.
The University of Exeter’s newly funded PATHS study exists precisely because so much psilocybin use already happens this way, with researcher Dr Hannah Farrimond arguing that the UK needs “urgent conversations about the benefits and risks of mainstreaming psychedelics before further regulation.” That unmet demand has a public face, too: UK cluster headache sufferers have directly petitioned Home Office ministers for psilocybin access rights, arguing existing treatments fail them. Enforcement of personal possession is inconsistent and low-priority in practice, but the criminal risk, and the total absence of quality control outside a lab, remain real.
Government Advisers Have Recommended Change, but Westminster Is Moving Cautiously
The pressure to loosen research restrictions has been building for years, with MPs from across the Commons repeatedly pressing ministers even as successive UK governments have delayed acting on psilocybin rescheduling. The House of Commons Home Affairs Committee recommended in 2023 that psychedelics with therapeutic potential move to the less restrictive Schedule 2, and the Advisory Council on the Misuse of Drugs followed with a report the same year setting out five ways to cut the cost and delay of studying Schedule 1 drugs such as psilocybin and MDMA.
The Home Office finally responded on 16 July 2025. It accepted recommendations to streamline licensing and build a framework for evaluating reform, and gave qualified backing, in principle and pending a pilot, to exempting universities and NHS trial sites that already hold Medicines and Healthcare products Regulatory Agency and ethics approval from also needing a separate Home Office Schedule 1 licence.
Citing ambiguity over manufacturing and supply, the Home Office rejected a proposal to let organisations already licensed for less restricted drugs handle Schedule 1 substances without extra licensing.
A cross-government working group now oversees that pilot, while Drug Science’s Medical Psychedelics Working Group.
No psychedelic medicine has yet secured full UK marketing authorisation, though the regulator’s Innovative Licensing and Access Pathway offers an accelerated route that psychedelic candidates could eventually use.
The US, EU and Australia Are Setting the Pace on Reform
Other jurisdictions have moved further and faster. In the United States, Oregon and Colorado both run state-regulated psilocybin service programmes, though roughly a third of Oregon’s licensed centres have closed under the weight of high fees and thin demand, even as federal policy has shifted: President Trump’s April 2026 executive order to accelerate psychedelic treatments for serious mental illness was followed by the U.S. Food and Drug Administration awarding national priority review vouchers to Compass Pathways, Transcend Therapeutics and the Usona Institute.
Within the EU, the Netherlands already permits legal sale of psilocybin truffles, Germany has gone further by pioneering a compassionate-use pathway for treatment-resistant depression described as an EU first. The European Medicines Agency has begun signalling openness to a more flexible, evidence-weighted approach to psychedelic drug approvals, and advocacy groups such as PAREA continue pressing the European Commission on equitable access to any future therapies.
Australia went furthest first, rescheduling psilocybin and MDMA in 2023 to allow prescribing through an Authorised Prescriber scheme. By late 2025 it had grown to 26 authorised psilocybin prescribers and 47 patients treated, with zero serious adverse events reported. Workforce capacity, not drug safety, now the scheme’s binding constraint.
Taken together, the picture is of a UK research base that is genuinely competitive internationally, sitting inside a legal framework that has barely moved since 1971. Ministers have accepted, in principle, that Schedule 1 status makes research needlessly slow and expensive, and a pilot scheme is now testing a narrow fix.
Rescheduling psilocybin itself —the change researchers and campaigners say would matter most— remains under review rather than under way. Until that changes, people most likely to benefit from psilocybin therapy in Britain will keep encountering it either inside a trial protocol or outside the law altogether.
